-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The new crown vaccination is in full swing, especially in the case of outbreaks in Guangzhou and Taiwan, people are becoming more and more active in vaccination against the new crown
.
So, can cancer patients get the new crown vaccine? At present, there is a lack of corresponding clinical trial data, and the safety and effectiveness of the new crown vaccine for cancer patients are still unclear
Can cancer patients get the new crown vaccine? At present, there is a lack of corresponding clinical trial data, and the safety and effectiveness of the new crown vaccine for cancer patients are still unclear.
Infect new crown pneumonia COVID-19 Efficacy of at The BNT162b2 COVID-19 mRNA Vaccine in patients with chronic lymphocytic leukemia Efficacy of at The BNT162b2 COVID-19 mRNA Vaccine in patients with chronic lymphocytic leukemia assess the protective effect of the vaccine on COVID-19 CLL patients
Herishanu et al.
evaluated the humoral immune response of CLL patients to the COVID-19 BNT162b2 messenger RNA (mRNA) vaccine and compared the response with matched age healthy control subjects
.
After the patient received two doses of vaccine 21 days apart, the antibody titer was detected by the Elecsys Anti-SARS-CoV-2 S assay
immunity
Anti-SARS-CoV-2 antibody response in CLL patients and healthy controls
Anti-SARS-CoV-2 antibody response in CLL patients and healthy controlsA total of 167 CLL patients were enrolled , and the antibody response rate was 39.
5%
.
The comparison of the response of 52 CLL patients and 52 gender- and age-matched healthy control subjects showed that the antibody response rate of CLL patients was significantly reduced (52% vs 100% ; adjusted odds ratio 0.
167 CLL patients with an antibody response rate of 39.
The effect of treatment on antibody response rate
The effect of treatment on antibody response rateAmong CLL patients, CLL patients who achieved clinical remission after treatment had the highest antibody response rate (79.
2%) , followed by untreated patients (55.
2%), and the antibody response rate of patients receiving anti-CLL treatment at the time of vaccination The lowest (16.
0%)
.
In patients treated with Bruton's tyrosine kinase inhibitor or Venetog±anti-CD20 antibody, the antibody response rate was quite low (16.
CLL patients who achieved clinical remission after treatment had the highest antibody response rate (79.
Independent predictors of antibody response include younger age, women, no active treatment at present, immunoglobulin G level ≥550 mg/dL and immunoglobulin M level ≥40 mg/dL .
The antibody-mediated response of CLL patients to the BNT162b2 mRNA vaccine of COVID-19 was significantly impaired, and was affected by the activity of CLL disease and treatment .
Original source:
Yair Herishanu, et al.
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia in this message
